Pharma and Biotech Update: Moderna, Merck, J&J, Regeneron, and More!

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Moderna faced a challenging year with declining share values, prompting analysts to recommend holding onto their stock. Meanwhile, Merck experienced setbacks in its cancer drug pipeline, leading to the termination of two candidates following disappointing late-stage results.In other news, J&J's FDA bid for subcutaneous Rybrevant was rejected due to manufacturing facility issues. On the other hand, Regeneron and Bayer are looking to expand into retinal vein occlusion with their drug Eylea amidst biosimilar competition.Intelligencia AI made headlines after successfully predicting high-potential biotechs before a conference, showcasing the reliability of its predictive methodology. Additionally, there have been FDA approvals in atopic dermatitis, layoffs at Outlook Therapeutics, and recent job postings in the biotech industry.